1 September 1998 in Journal of Clinical Ultrasound
6 December 2022 in Cardiology in the Young
Objective: We aimed to evaluate the efficacy of combined (ibuprofen+paracetamol) medical therapy in cases of persistent haemodynamically significant patent ductus arteriosus that are resistant to standard medical monotherapy (ibuprofen and/or paracetamol) in this retrospective multi-centre study.Methods: The combined therapy included the administration of 15mg/kg/dose of paracetamol every 6 h for 3 days and ibuprofen at an initial dose of 10mg/kg/dose followed by 5 mg/kg/dose every 24 h. After 2 days following the administration of the last dose, the researchers evaluated the efficacy of combined treatment by conducting an echocardiographic examination.Results: Of all 42 patients who received combined therapy, 37 (88.1%) patients exhibited closure of the haemodynamically significant patent ductus arteriosus without requiring surgical ligation. Patients who did not respond to combined therapy had a higher mean birth weight and gestational age compared to those who responded (p < 0.05).Conclusion: The researchers believe the success of ibuprofen and paracetamol in haemodynamically significant patent ductus arteriosus treatment may be due to their synergistic efficacy and inhibition of the prostaglandin synthesis pathway through different enzymes. The results of our retrospective trial suggest that combination therapy with paracetamol and ibuprofen can be attempted when monotherapy is unsuccessful in treating haemodynamically significant patent ductus arteriosus, especially in centres without a surgical department.
13 April 2024 in Pediatric Neurology
15 May 2022 in Iranian Journal of Pediatrics
Background: Coronavirus disease 2019 (COVID-19) has been infecting children since December 2019 and has caused a severe epidemic and millions of deaths worldwide. COVID-19 has severe clinical effects and is more complicated to manage in patients with underlying diseases, such as congenital heart disease (CHD), past surgical operations, arrhythmia, and end-organ damage. Objectives: This study aimed to evaluate the clinical course, follow-up, and treatment process of patients with CHD and COVID-19 in Inonu University Faculty of Medicine, Department of Pediatrics, Turkey during March 2020-February 2021. Methods: This retrospective study was performed on patients with CHD and COVID-19 in the Department of Pediatrics at Inonu University Faculty of Medicine during March 2020-February 2021, selected by making full count sampling. Admission complaints, clinical findings, biochemical parameters, echocardiography results, hospitalization times, treatments, and clinical follow-up findings were retrieved from patients' files. Results: 11 patients with underlying CHD and COVID-19 were evaluated retrospectively during the study. Ten patients were hospitalized and treated due to COVID-19. Treatment of seven of these patients continued in the intensive care unit (ICU), and five were followed up under a mechanical ventilator. Two patients died during follow-up in the ICU. Conclusions: The clinical course of COVID-19 is severe, and the mortality rate is high in patients with serious diseases, such as underlying CHD. Therefore, COVID-19 in patients with CHD requires more serious and careful follow-up.
1 June 2025 in Atlas Universitesi Tip ve Saglik Bilimleri Dergisi
Çocuklarda kalp yetmezliği (KY), kalbin vücudun metabolik ihtiyaçlarını karşılayamaması olarak tanımlanan klinik bir sendromdur. Natriüretik peptitler ve kardiyak troponinler, KY’ nin tanısı ve prognozu için en çok kullanılan kardiyovasküler biyobelirteçlerdir. KY’ de tanı, prognoz ve risk sınıflandırmasıyla ilgili birçok başka biyobelirteç de tanımlanmıştır. Bu çalışmada, kardiyak miyozin bağlayıcı protein-C’ nin (cMyBP-C) prognostik değerinin, klinisyen tarafından çocuklarda yeni teşhis edilen KY’ yi değerlendirirken kullanılabilecek olası yeni bir biyobelirteç olup olmadığını araştırmayı amaçladık. Bu, konjestif kalp yetmezliği (KKY) olan 24 çocuk ve 30 sağlıklı çocuğu içeren prospektif bir vaka kontrol çalışmasıdır. Tıbbi öykü ve fizik muayene alındıktan sonra hastalar elektrokardiyografi, telekardiyografi ve ekokardiyografi ile değerlendirildi ve modifiye edilmiş bir Ross skorlaması yapıldı. Plazma cMyBP-C ve diğer biyobelirteç N-terminal pro-natriüretik peptid (NT-proBNP) değerleri, rutin kan testleri, karaciğer enzimleri başvuru sırasında ölçüldü. Hasta grubunun ortalama cMyBP-C (ng/ml) plazma düzeyi 1.55 ng/ ml (0.1-9.4), kontrol grubunun ise 0.1 ng/ml (0.3-1) idi (p<0.01). Etiyolojik araştırmanın değerlendirilmesi sonrasında miyokardit grubunda saptanan ortalama plazma cMyBP-C düzeyi 1.9 ng/ml (0.1-3.1) idi. Buna göre hasta grubunda cMyBP-C’nin ortalama değeri kontrol grubundan anlamlı olarak yüksek olup akut miyokardit grubunda en yüksekti (p<0.01). CMyBP-C, akut KY’ li çocuklarda yeni ve yararlı bir tanı ve prognoz biyobelirteci olabilir.
28 November 2022 in The Anatolian Journal of Cardiology